Evidence map›Paper›PMID 31127887›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2019

Detection of Epidermal Growth Factor Receptor (EGFR) Gene Mutation in Formalin Fixed Paraffin Embedded Tissue by Polymerase Chain Reaction-Single Strand Conformational Polymorphism (PCR-SSCP) in Non-Small Cell Lung Cancer in the Northeastern Region of Thailand

Kornsiri Saiyaros, Panutas Kritpetcharat, Chawalit Pairojkul, Jiraporn Sithithaworn

Open access · goldAbstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Kornsiri SaiyarosDepartment of Clinical Microscopy, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen,Thailand. Email: Kornsiri_mt@hotmail.com
Panutas KritpetcharatDepartment of Clinical Microscopy, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen,Thailand. Email: Kornsiri_mt@hotmail.com
Chawalit PairojkulDepartment of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Jiraporn SithithawornDepartment of Clinical Microscopy, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen,Thailand. Email: Kornsiri_mt@hotmail.com
Khon Kaen University · THMahasarakham University · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The use of targeted specific genes in therapeutic and treatment decisions has been considered for lung cancer. The epidermal growth factor receptor (EGFR) gene, which is over expressed in non-small cell lung cancer (NSCLC), was considered as one of the targeted specific genes. EGFR mutations in exons 18–21, which encode a portion of the EGFR kinase domain, were found in NSCLC patients and were associated with the response of EGFRtyrosine kinase inhibitors (EGFR-TKIs). Therefore, a molecular technique for EGFR mutation detection has important benefits for therapy in NSCLC patients. This study aims to determine the EGFR mutations in patients with NSCLC using polymerase chain reaction-single strand conformational polymorphism (PCR-SSCP) in exons 18-21. Methods: DNA samples were extracted from formalin fixed paraffin embedded tissues of NSCLC patients who attended hospital. The extracted DNA was used as a template for the EGFR gene amplification. Results: Occurrence of EGFR mutations were found in 29 out of 50 cases (58%).The frequency of EGFR mutations by first PCR at exon 18, 19, 20 and 21 were 6 (12%), 19 (38%) 20 (40%) and at 21 (42%), respectively. By PCR-SSCP, the frequencies of EGFR mutations at exon 18, 19, 20 and 21 were 3(6%), 18(36%), 23(46%) and 13(26%), respectively. All of the mutations found were in agreement with DNA sequencings. Conclusion: The high frequency of EGFR mutations in NSCLC suggests that PCR-SSCP is a efficient screening method and useful for treatment plan.

Indexed as

MutationPolymorphism, Single-Stranded ConformationalAdenocarcinomaAdenocarcinoma, Bronchiolo-AlveolarAdultAgedBase SequenceBiomarkers, TumorCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCase-Control StudiesErbB ReceptorsFemaleFollow-Up StudiesFormaldehydeHumansBiomarkers, TumorEGFR protein, humanErbB ReceptorsFormaldehydeEpidermal growth factor receptorpolymerase chain reactionsingle strand conformational polymorphism

Identifiers

PMID31127887
PMCPMC6857892
OpenAlexW2946192503

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.